Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator

Chemistry and Biology

Volumn 7, Issue 4, 2000, Pages 299-312

  Katz, Bradley A ^a   Mackman, Richard ^a   Luong, Christine ^a   Radika, Kesavan ^a   Martelli, Arnold ^a   Sprengeler, Paul A ^a   Wang, Jing ^a   Chan, Hedy ^a   Wong, Lance ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

S1 structure; Thrombin; tPA; Trypsin; uPA

Indexed keywords

EID: 0034176413     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00104-6     Document Type: Article

References (31)

1. Schechter I., Berger A. On the size of the active site in proteinases. I. Papain. Biochem. Biophys. Res. Commun. 27:1967;157-162.
2. Renatus M., Bode W., Huber R., Stürzebecher J., Stubbs M.T. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J. Med. Chem. 41:1998;5446-5456.
3. Maduskie T.P. Jr., McNamura K.J., Ru Y., Knabb R.M., Stouten P.F.W. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J. Med. Chem. 41:1998;53-62.
4. Gabriel B., Moroder L. Structure-based design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 41:1998;4240-4250.
5. Brandstetter H., Engh R.A.et al. X-ray structure of active site-inhibited clotting factor Xa: implications for drug design and substrate recognition. J. Biol. Chem. 271:1996;29988-29992.
6. Towle M.J., Lee A., Maduakor E.C., Schwartz C.E., Bridges A.J., Littlefield B.A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. 53:1993;2553-2559.
7. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Shriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:1985;139-266.
8. Andreasen P.A., Kjøller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72:1997;1-22.
9. Rabbani S.A., Xing R.H.M. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12:1998;911-920.
10. Stack M.S., Ellerbroek S.M., Fishman D.A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol. 12:1998;569-576.
11. Magill C., Katz B.A., Mackman R. Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system. Emerging Therapeutic Targets. 3:1999;109-133.
12. Lambda D., Bode W.et al. The 2.3 Å crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J. Mol. Biol. 258:1996;117-135.
13. Spraggon G., Jones E.Y.et al. The crystal structure of the catalytic domain of human urokinase-type plaminogen activator. Structure. 3:1995;681-691.
14. +2 to mediate potent specific inhibition of serine proteases. J. Mol. Biol. 292:1999;669-684.
15. Perrin, D.D. (1965). Dissociation constants of organic bases in aqueous solution. Supplement to Pure and Applied Chemistry, International Union of Pure and Applied Chemistry, London, Butterworths.
16. Bernstein F.C., Tasumi M.et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 112:1977;535-542.
17. Holmberg L., Bladh B., Astedt B. Purification of urokinase by affinity chromatography. Biochim. Biophys. Acta. 445:1976;215-222.
18. Bridges, A., Littlefield, B.A., Schwartz, C.E. Urokinase Inhibitors. 23 August 1994, US Patent 5340833.
19. Bhat B., Bhaduri A.P. A Novel one-step synthesis of 2-methoxycarbonylthieno[2, 3-b]quinolines and 3-hydroxy-2-methoxycarbonyl-2-3-dihydrothieno[2, 3-b]-quinolines. Synthesis. 8:1984;673-676.
20. Meth-Cohn O., Narine B. A versatile new synthesis of quinolines, thienopyridines and related fused pyridines. Tetrahedron Lett. 23:1978;2045-2048.
21. Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal. Biochem. 237:1996;260-273.
22. Cleland W.W. Statistical analysis of enzyme kinetic data. Methods Enzymol. 63:1979;103-138.
23. Jancarik J., Kim S.H. Sparse matrix sampling: a screening method for crystallization of proteins. J. Appl. Crystallogr. 25:1991;408-411.
24. Skrzpczak-Jankun E., Carperos V.E., Ravichandran K.G., Tulinsky A., Westbrook M., Maraganore J.M. Structure of the hirugen and hirulog 1 complexes of α-thrombin. J. Mol. Biol. 221:1991;1379-1393.
25. Chmielewska, J., Lundqvist, T., Mosialou, E., Ogg, D. Modified human factor Xa. 7 February 1998, International patent WO 98/28412.
26. Katz B.A., Liu B., Barnes M., Springman E.B. Crystal structure of recombinant human tissue kallikrein at 2.0 Å resolution. Protein Sci. 7:1998;875-885.
27. Padmanabhan K., Kisiel W.et al. Structure of human des(1-45) factor Xa at 2.2 Å resolution. J. Mol. Biol. 232:1993;947-966.
28. Vijayalakshmi J., Padmanabhan K.P., Mann K.G., Tulinsky A. The isomorphous structures of prethrombin2, hirugen- and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci. 3:1994;2254-2271.
29. i ∼ nanomolar inhibitors of serine proteases by binding or epitaxial chemistry on an enzyme surface. Biochemistry. 34:1995;8264-8280.
30. Frisch M.J., Pople J.A.et al. Gaussian 94, Revision E.3. 1995;Gaussian, Inc, Pittsburgh PA.
31. Schlegel H.B. Optimization of equilibrium geometries and transition structures. J. Comp. Chem. 3:1982;214.